Loading clinical trials...
Loading clinical trials...
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults with Generalized Anxiety Disorder.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Cephalon
NCT06066983 · Autism Spectrum Disorder, Anxiety Disorders
NCT06968026 · Recurrent Pregnancy Loss, Anxiety Disorders
NCT07174947 · Hepatobiliary Malignancy, Fluoxetine, and more
NCT07432945 · Anxiety, Anxiety Disorders
NCT06661460 · ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Specific Phobia, and more
Birmingham Research Group
Birmingham, Alabama
Pivotal Research Center
Mesa, Arizona
Pivotal Research
Peoria, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions